Immunicum reports preliminary regression data after add-on therapy with tyrosine kinase inhibitors and continued compelling survival data from the formally completed phase I/II-study in renal cell carcinoma
In addition to continued convincing survival data from the formally completed phase I/II-study in metastatic renal cell carcinoma, preliminary INTUVAX-data now also shows a remarkable partial regression of all metastases in two patients who received add-on therapy with tyrosine kinase inhibitors after INTUVAX-treatment. These findings suggest that combination treatment with INTUVAX and certain tyrosine kinase inhibitors can have a synergistic antitumor effect.
The Company also announced that two patients, whose tumor metastases after INTUVAX-therapy progressed, received add-on therapy with tyrosine kinase inhibitors and subsequently showed remarkable regression of all remaining metastases. In one case, a patient had four brain metastases of which two have gone into complete remission and the remaining two into a continued extensive partial regression. The second case involves a patient with extensive sarcomatoid tumor development, which also showed a partial regression of all metastases. According to the current established knowledge neither of these two patients should have responded to treatment with tyrosine kinase inhibitors.
A scientific abstract with data from Immunicum’s phase I/II-study in metastatic renal cell cancer will be presented at the world’s largest cancer conference, the annual ASCO-meeting in Chicago, May 30 – June 3. The Company continues to collect data from the study and plans to announce overall information on the data collected until the time of the ASCO-conference, expected on June 2nd.
Read the press release here: Press release 140521 – Regression data